Menu
Search
|

Menu

Close
X

Nightstar Therapeutics PLC NITE.OQ (NASDAQ Stock Exchange Global Select Market)

25.31 USD
-- (--)
As of Mar 21
chart
Previous Close 25.31
Open --
Volume --
3m Avg Volume 59,223
Today’s High --
Today’s Low --
52 Week High 28.38
52 Week Low 9.62
Shares Outstanding (mil) 33.48
Market Capitalization (mil) 847.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.56 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
EPS (USD)
FY18
-1.282
FY17
-1.626
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.45
Price to Sales (TTM)
vs sector
--
9.03
Price to Book (MRQ)
vs sector
5.12
4.61
Price to Cash Flow (TTM)
vs sector
--
40.28
Total Debt to Equity (MRQ)
vs sector
0.00
17.70
LT Debt to Equity (MRQ)
vs sector
0.00
14.01
Return on Investment (TTM)
vs sector
-25.30
12.08
Return on Equity (TTM)
vs sector
-25.30
13.20

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9-10 Midford Place
LONDON   MA   W1T 5BJ

Phone: +4420.76112077

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.

SPONSORED STORIES